AUTL News and Press, Autolus Therapeutics plc From 08/02/21

LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an agreement with Moderna, a biotechnology company pioneering messenger RNA (mRNA) thera...

AUTL is a UK-based developer of CAR-T. It claims a better tax profile than Tecartus in adult r/r ALL. Price is currently depressed. For further details see: Autolus: Developing Better CAR-T In Refractory ALL

LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle...

LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlight...

LONDON, June 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway (ILAP) designation from the...

Autolus Therapeutics (AUTL) presents data related to AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed/refractory (r/r) indolent B cell lymphomas ((IBCL)) and r/r adult Acute Lymphoblastic Leukemia ((ALL)) at EHA 2021. AUTO1 results in r/r IBCL patients:As of the data cut-off date of ...

LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Nature Cancer that gives new insight into the mechanism of long-term dur...

Attendance in person is not permitted LONDON, May 21, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to ...

Shares of Autolus Therapeutics (NASDAQ: AUTL) were trading 35% higher as of 3:37 p.m. EDT on Wednesday. Those big gains came after the company announced that its experimental CD19 cell therapy, AUTO1, had achieved 100% remission in patients with relapsed/refractory indolent non-Hodg...

Autolus Therapeutics ([[AUTL]] +33.3%) has surged today in reaction to impressive results from a Phase 1 trial for its CD19 CAR T cell therapy AUTO1 in relapsed / refractory (r/r) indolent B cell lymphomas ((IBCL)).The data is included in an abstract presentation to be unveiled at t...